Oricell Raises Over $110 Million in Pre-IPO Round to Speed Global CAR-T Expansion

New updates have been reported about Oricell Therapeutics Holdings Limited.

Oricell Therapeutics Holdings Limited has closed a pre-IPO financing round exceeding $110 million, providing substantial capital to accelerate its global clinical programs and sharpen its push toward future capital market listings. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a major global healthcare fund, with participation from a sovereign wealth fund and several institutional investors, underscoring strong confidence in Oricell’s oncology cell therapy strategy.

Management plans to deploy the proceeds to expand international operations, advance pivotal trials for its lead GPC3-targeted CAR-T candidate Ori-C101 in advanced hepatocellular carcinoma, and strengthen its proprietary platforms for antibody discovery, T-cell armoring, and rapid manufacturing. Clinical data from Ori-C101 and its multiple myeloma candidate OriCAR-017, which has already secured IND approvals in China and the U.S. along with FDA Orphan Drug and Fast Track designations, position Oricell as a potential first mover in solid tumor CAR-T and support its ambition for global regulatory and commercial execution.

Backers highlight Oricell’s differentiated “platform plus pipeline” model and its focus on hard-to-treat solid tumors as key reasons for their investment, viewing cell therapy as a growth area where the company could establish new standards of care. With confirmatory proof-of-concept data across several programs, upcoming pivotal studies, and a stated priority to push into in vivo and next-generation CAR-T modalities, Oricell is entering a capital- and execution-intensive phase where trial outcomes, regulatory milestones, and the timing of an eventual IPO will be critical for valuation, partnering opportunities, and long-term competitive positioning in the global immunotherapy market.